Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX2 tumor in rabbits by intravenous injection

Table 1 Change of average weight of animals in each group mean ± SD

Group	n	Weight (kg)
		Before injection	One week after injection	Three weeks after injection
A (Control)	12	2.73 ± 0.21	2.67 ± 0.21	2.32 ± 0.14
B (HAP)	11	2.66 ± 0.15	2.59 ± 0.14	2.46 ± 0.19ad
C (HAP)	12	2.70 ± 0.16	2.61 ± 0.14	2.52 ± 0.12ad
D (5-FU)	11	2.70 ± 0.17	2.47 ± 0.17a	1.95 ± 0.14b
E (5-FU + HAP)	12	2.78 ± 0.19	2.60 ± 0.18	2.23 ± 0.22d

^aP < 0.05,

^bP < 0.01, vs group A;

^dP < 0.01, vs group D.

Table 2 ALT level before and after treatment in each group mean ± SD

Group	n	ALT (U/ L)
		Beforeinjection	One week after injection	Three weeks after injection
A (Control)	12	43.56 ± 7.24	45.33 ± 8.29	75.33 ± 12.51
B (Nano HAP)	11	39.29 ± 6.52	42.73 ± 10.05d	59.55 ± 15.40ad
C (Nano HAP)	12	40.38 ± 6.88	43.75 ± 6.30d	62.00 ± 14.49ad
D (5-FU)	11	42.70 ± 7.08	74.64 ± 15.55b	99.73 ± 14.70b
E (5-FU + HAP)	12	42.86 ± 6.79	59.67 ± 12.66bc	86.42 ± 11.54ac

^aP < 0.05,

^bP < 0.01, vs A group;

^cP < 0.05,

^dP < 0.01, vs D group.

Table 3 Tumor volume and tumor growth inhibition rate of each group 3 wk after treatment mean ± SD

Group	Gross tumorvolume (cm3)	Inhibitionratio (%)	t value(vs group)
A (control)	33.32 ± 5.26	—	—
B (Nano HAP)	24.81 ± 5.17bd	25.53	3.91
C (Nano HAP)	22.73 ± 4.23bd	32.52	5.29
D5-FU	18.74 ± 4.40bd	43.7	7.17
E (5-FU + HAP)	13.10 ± 2.48b	60.97	12.05

^bP < 0.01 vs group A;

^dP < 0.01 vs group E.

Table 4 P53 and c-Myc positive staining in groups

Group	n	P53				Positive(%)	c-Myc				Positive(%)
		-	+	++	+++		-	+	++	+++
A	12	2	4	5	1	83.3	3	5	3	1	75.0
B	23	13	6	4	0	43.5a	12	5	5	1	47.8
D	11	6	2	3	0	45.5	5	2	3	1	54.5
E	12	7	3	2	0	41.7	6	3	3	0	50.0

^aP = 0.034 vs group A.